Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10148
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAkcılar, Raziye-
dc.contributor.authorTurgut, Sebahat-
dc.contributor.authorCaner, Vildan-
dc.contributor.authorAkcilar, A.-
dc.contributor.authorAyada, C.-
dc.contributor.authorElmas, L.-
dc.contributor.authorÖzcan, T.O.-
dc.date.accessioned2019-08-16T13:12:29Z
dc.date.available2019-08-16T13:12:29Z
dc.date.issued2015-
dc.identifier.issn1896-1126-
dc.identifier.urihttps://hdl.handle.net/11499/10148-
dc.identifier.urihttps://doi.org/10.1016/j.advms.2014.11.001-
dc.description.abstractPurpose: Apelin is an adipokine that plays a role in the regulation of many biological functions in mammals including the neuroendocrine, cardiovascular, immune systems, glucose homeostasis and obesity. It can act via autocrine, paracrine, endocrine, and exocrine signaling. We aimed to identify the role of apelin pathophysiology of diabetes. Material/methods: 37 male Wistar Albino rats aged 8-10 weeks were divided in four experimental groups as: control group (C) control + apelin group (C + A), diabetic group (D) diabetic + apelin group (D + A). Apelin and apelin receptor mRNA gene expressions in heart and aorta tissue were determined by real-time polymerase chain reaction. The plasma levels of insulin and plasma apelin were determined by ELISA. Results Plasma levels of insulin, glucose, blood pressure levels were significantly lower in D + A group. There was no statistically significant difference for level of apelin between diabetic groups. On the other hand, differences for apelin and APJ mRNA expression in heart and vascular tissue were found significant between groups. Conclusions: Apelin can be used as a therapeutic agent in the treatment of type II diabetes in the future. © 2014 Medical University of Bialystok.en_US
dc.language.isoenen_US
dc.publisherMedical University of Bialystoken_US
dc.relation.ispartofAdvances in Medical Sciencesen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlloxanen_US
dc.subjectApelinen_US
dc.subjectApelin receptor (APJ)en_US
dc.subjectBlood pressureen_US
dc.subjectGlucose metabolismen_US
dc.subjectType II diabetesen_US
dc.subjectangiotensin IIen_US
dc.subjectangiotensinogenen_US
dc.subjectantidiabetic agenten_US
dc.subjectapelinen_US
dc.subjectapelin receptoren_US
dc.subjectendothelin 1en_US
dc.subjectglucoseen_US
dc.subjectinsulinen_US
dc.subjectmessenger RNAen_US
dc.subjectpeptide derivativeen_US
dc.subjectpyroglutamylated apelin 13en_US
dc.subjectunclassified drugen_US
dc.subjectAPLN protein, humanen_US
dc.subjectAPLNR protein, humanen_US
dc.subjectG protein coupled receptoren_US
dc.subjectsignal peptideen_US
dc.subjectangiotensin blood levelen_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectanimal tissueen_US
dc.subjectantidiabetic activityen_US
dc.subjectArticleen_US
dc.subjectblood pressureen_US
dc.subjectblood pressure measurementen_US
dc.subjectbody weighten_US
dc.subjectcontrolled studyen_US
dc.subjectenzyme linked immunosorbent assayen_US
dc.subjectgene expressionen_US
dc.subjectglucose blood levelen_US
dc.subjecthearten_US
dc.subjectheart weighten_US
dc.subjectinsulin blood levelen_US
dc.subjectmaleen_US
dc.subjectmolecular pathologyen_US
dc.subjectnon insulin dependent diabetes mellitusen_US
dc.subjectnonhumanen_US
dc.subjectprotein blood levelen_US
dc.subjectraten_US
dc.subjectreal time polymerase chain reactionen_US
dc.subjectrenin angiotensin aldosterone systemen_US
dc.subjectvascular tissueen_US
dc.subjectWistar raten_US
dc.subjectanimalen_US
dc.subjectblooden_US
dc.subjectDiabetes Mellitus, Type 2en_US
dc.subjectdrug effectsen_US
dc.subjectgeneticsen_US
dc.subjectmetabolismen_US
dc.subjectAnimalsen_US
dc.subjectBlood Pressureen_US
dc.subjectHypoglycemic Agentsen_US
dc.subjectInsulinen_US
dc.subjectIntercellular Signaling Peptides and Proteinsen_US
dc.subjectMaleen_US
dc.subjectRatsen_US
dc.subjectRats, Wistaren_US
dc.subjectReceptors, G-Protein-Coupleden_US
dc.subjectRNA, Messengeren_US
dc.titleThe effects of apelin treatment on a rat model of type 2 diabetesen_US
dc.typeArticleen_US
dc.identifier.volume60en_US
dc.identifier.issue1en_US
dc.identifier.startpage94
dc.identifier.startpage94en_US
dc.identifier.endpage100en_US
dc.identifier.doi10.1016/j.advms.2014.11.001-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid25625368en_US
dc.identifier.scopus2-s2.0-84927748550en_US
dc.identifier.wosWOS:000358555200015en_US
dc.identifier.scopusqualityQ2-
dc.ownerPamukkale University-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.dept14.03. Basic Medical Sciences-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

28
checked on Dec 14, 2024

WEB OF SCIENCETM
Citations

25
checked on Dec 20, 2024

Page view(s)

56
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.